Analysts expect Henry Schein, Inc. (NASDAQ:HSIC) to post $3.31 billion in sales for the current quarter, Zacks Investment Research reports. Nine analysts have provided estimates for Henry Schein’s earnings, with the lowest sales estimate coming in at $3.21 billion and the highest estimate coming in at $3.36 billion. Henry Schein posted sales of $3.12 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 6.1%. The company is expected to announce its next quarterly earnings results on Tuesday, February 20th.

On average, analysts expect that Henry Schein will report full year sales of $3.31 billion for the current financial year, with estimates ranging from $12.29 billion to $12.54 billion. For the next year, analysts anticipate that the firm will post sales of $13.20 billion per share, with estimates ranging from $12.99 billion to $13.36 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Henry Schein.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Monday, November 6th. The company reported $0.87 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.90 by ($0.03). The company had revenue of $3.16 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.84 earnings per share.

HSIC has been the subject of several research analyst reports. Morgan Stanley cut shares of Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 target price for the company. in a research note on Wednesday, December 6th. Craig Hallum upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Tuesday, November 7th. Piper Jaffray Companies reiterated a “buy” rating and set a $78.00 price objective on shares of Henry Schein in a research report on Wednesday, December 27th. Credit Suisse Group reiterated a “neutral” rating and set a $80.00 price objective (down previously from $87.50) on shares of Henry Schein in a research report on Tuesday, November 28th. Finally, Zacks Investment Research lowered shares of Henry Schein from a “hold” rating to a “sell” rating in a research report on Monday, November 13th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $84.23.

Henry Schein (HSIC) traded up $1.34 on Thursday, reaching $75.96. 1,128,221 shares of the company traded hands, compared to its average volume of 1,223,579. The stock has a market capitalization of $11,922.23, a PE ratio of 21.89, a price-to-earnings-growth ratio of 1.94 and a beta of 1.00. Henry Schein has a 52 week low of $65.28 and a 52 week high of $93.50. The company has a quick ratio of 0.86, a current ratio of 1.55 and a debt-to-equity ratio of 0.30.

In other news, Director Barry J. Alperin sold 5,796 shares of the firm’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $70.76, for a total value of $410,124.96. Following the completion of the sale, the director now owns 48,172 shares in the company, valued at approximately $3,408,650.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.19% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in HSIC. YorkBridge Wealth Partners LLC lifted its holdings in shares of Henry Schein by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock worth $104,000 after acquiring an additional 28 shares during the last quarter. Sun Life Financial INC lifted its holdings in shares of Henry Schein by 8,185.7% in the 2nd quarter. Sun Life Financial INC now owns 580 shares of the company’s stock worth $106,000 after acquiring an additional 573 shares during the last quarter. FTB Advisors Inc. lifted its holdings in shares of Henry Schein by 100.0% in the 3rd quarter. FTB Advisors Inc. now owns 1,484 shares of the company’s stock worth $120,000 after acquiring an additional 742 shares during the last quarter. Trust Co. of Vermont lifted its holdings in shares of Henry Schein by 56.7% in the 3rd quarter. Trust Co. of Vermont now owns 1,702 shares of the company’s stock worth $140,000 after acquiring an additional 616 shares during the last quarter. Finally, Lee Financial Co lifted its holdings in shares of Henry Schein by 100.0% in the 3rd quarter. Lee Financial Co now owns 1,756 shares of the company’s stock worth $144,000 after acquiring an additional 878 shares during the last quarter. Hedge funds and other institutional investors own 91.70% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “$3.31 Billion in Sales Expected for Henry Schein, Inc. (HSIC) This Quarter” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2018/01/22/3-31-billion-in-sales-expected-for-henry-schein-inc-hsic-this-quarter.html.

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.